Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Microbiome
|
June 15, 2021
Review: microbial transformations of human bile acids
Douglas V Guzior, Robert A Quinn
Nature Metabolism
|
May 10, 2023
A multi-omic trip through the human gut
Robert A Quinn, Christian Martin, Douglas V Guzior
Journal of Lipid Research
|
November 29, 2025
Serum cholic acid and cecal Faecalibaculum increase in a male-specific manner in a murine hepatocellular carcinoma model
Angela E Dean, Douglas V Guzior, Robert A Quinn, et al.
Frontiers in Cell and Developmental Biology
|
February 20, 2024
Glucocorticoid-induced osteoporosis is prevented by dietary prune in female mice
Nicholas J Chargo, Kerri Neugebauer, Douglas V Guzior, et al.
Frontiers in Cellular and Infection Microbiology
|
May 23, 2024
Shifts in the functional capacity and metabolite composition of the gut microbiome during recovery from enteric infection
Zoe A Hansen, Anthony L Schilmiller, Douglas V Guzior, et al.
Frontiers in Oncology
|
March 6, 2026
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth
Peter Cornelius, Benjamin A Mayes, Andrew J Dannenberg, et al.
Communications Biology
|
November 14, 2024
Longitudinal analyses of infants' microbiome and metabolome reveal microbes and metabolites with seemingly coordinated dynamics
Hao Wu, Douglas V Guzior, Christian Martin, et al.
Nature Communications
|
April 10, 2025
Balance between bile acid conjugation and hydrolysis activity can alter outcomes of gut inflammation
Yousi Fu, Douglas V Guzior, Maxwell Okros, et al.
Cell Reports
|
December 15, 2021
Streptozotocin-induced hyperglycemia alters the cecal metabolome and exacerbates antibiotic-induced dysbiosis
Jenna I Wurster, Rachel L Peterson, Claire E Brown, et al.
Research Square
|
October 16, 2023
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
Christian Martin, Douglas V Guzior, Cely T Gonzalez, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Microbiome
|
June 15, 2021
Review: microbial transformations of human bile acids
Douglas V Guzior, Robert A Quinn
Nature Metabolism
|
May 10, 2023
A multi-omic trip through the human gut
Robert A Quinn, Christian Martin, Douglas V Guzior
Journal of Lipid Research
|
November 29, 2025
Serum cholic acid and cecal Faecalibaculum increase in a male-specific manner in a murine hepatocellular carcinoma model
Angela E Dean, Douglas V Guzior, Robert A Quinn, et al.
Frontiers in Cell and Developmental Biology
|
February 20, 2024
Glucocorticoid-induced osteoporosis is prevented by dietary prune in female mice
Nicholas J Chargo, Kerri Neugebauer, Douglas V Guzior, et al.
Frontiers in Cellular and Infection Microbiology
|
May 23, 2024
Shifts in the functional capacity and metabolite composition of the gut microbiome during recovery from enteric infection
Zoe A Hansen, Anthony L Schilmiller, Douglas V Guzior, et al.
Frontiers in Oncology
|
March 6, 2026
Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth
Peter Cornelius, Benjamin A Mayes, Andrew J Dannenberg, et al.
Communications Biology
|
November 14, 2024
Longitudinal analyses of infants' microbiome and metabolome reveal microbes and metabolites with seemingly coordinated dynamics
Hao Wu, Douglas V Guzior, Christian Martin, et al.
Nature Communications
|
April 10, 2025
Balance between bile acid conjugation and hydrolysis activity can alter outcomes of gut inflammation
Yousi Fu, Douglas V Guzior, Maxwell Okros, et al.
Cell Reports
|
December 15, 2021
Streptozotocin-induced hyperglycemia alters the cecal metabolome and exacerbates antibiotic-induced dysbiosis
Jenna I Wurster, Rachel L Peterson, Claire E Brown, et al.
Research Square
|
October 16, 2023
Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy
Christian Martin, Douglas V Guzior, Cely T Gonzalez, et al.
Page
of 2